Global Blood Therapeutics clinical trials
Acquired by Pfizer, Oct 5, 2022 · source ↗
The registry lists 9 studies whose lead sponsor is Global Blood Therapeutics. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 20, 2020.
- 9studies on the registry
- 0open to participants now
Before and after it joined Pfizer
- First submitted before Global Blood Therapeutics became part of Pfizer
- 9
- First submitted after Global Blood Therapeutics became part of Pfizer
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Global Blood Therapeutics’ studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- 0 open · 9
All 9 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 14
- 15
- 516
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Global Blood Therapeutics9 studies
Something wrong with this grouping? Tell us on the Pfizer page.
Studies
Recruiting first, then most recently updated. Showing 9 of 9. All Pfizer studies →
- Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPFCompletedNCT02846324Phase 2
Sponsor listed in the registry: Global Blood Therapeutics · First submitted before Global Blood Therapeutics became part of Pfizer
- Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at RestTerminatedNCT02989168Phase 2
Sponsor listed in the registry: Global Blood Therapeutics · First submitted before Global Blood Therapeutics became part of Pfizer
- Study to Evaluate Effects of Investigational Drug on Oxygenation in Healthy Volunteers Under Hypoxic ConditionsTerminatedNCT03051711Phase 1
Sponsor listed in the registry: Global Blood Therapeutics · First submitted before Global Blood Therapeutics became part of Pfizer
- An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001CompletedNCT03041909Phase 2
Sponsor listed in the registry: Global Blood Therapeutics · First submitted before Global Blood Therapeutics became part of Pfizer
- Single-Dose PK Study of GBT440 in Subjects With Renal ImpairmentCompletedNCT03161015Phase 1
Sponsor listed in the registry: Global Blood Therapeutics · First submitted before Global Blood Therapeutics became part of Pfizer
- A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell DiseaseCompletedNCT02285088Phase 1
Sponsor listed in the registry: Global Blood Therapeutics · First submitted before Global Blood Therapeutics became part of Pfizer
- Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy SubjectsCompletedNCT02567682Phase 1
Sponsor listed in the registry: Global Blood Therapeutics · First submitted before Global Blood Therapeutics became part of Pfizer
- A Study of the Absorption, Metabolism, and Excretion of GBT440 in Healthy Male SubjectsCompletedNCT02497924Phase 1
Sponsor listed in the registry: Global Blood Therapeutics · First submitted before Global Blood Therapeutics became part of Pfizer
- A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy SubjectsCompletedNCT02567695Phase 1
Sponsor listed in the registry: Global Blood Therapeutics · First submitted before Global Blood Therapeutics became part of Pfizer